PLATINUM Partner

Sillajen

SillaJen Inc (Busan and Seoul, S Korea) is the global leader in the development of oncolytic vaccinia immunotherapy with Pexa-Vec (aka JX-594; previously Jennerex Inc) for primary hepatocellular carcinoma (HCC). We reported IV delivery of Pexa-Vec to diverse solid tumors (Nature 2011), and improved overall survival in a randomized dose-finding clinical trial (Nature Med 2013). Initiation of a Phase 3 clinical trial is planned for 2015. Patients with advanced first-line HCC will be randomized to treatment with Pexa-Vec followed by sorafenib versus sorafenib alone, with a primary endpoint of overall survival duration.

Oxford Genetics

Oxford Genetics is a synthetic biology company taking an engineering approach to DNA, virus and cell line design, optimization and development. The business has a number of technologies enabling the delivery of complex solutions for the life sciences, including proprietary plasmids for protein manufacture, and improved lentivirus production systems for gene therapy applications. These systems include proprietary promoters to maximize yield and have been developed using proprietary bioinformatics software for gene optimization. Our proprietary bioinformatics and DNA design algorithms are designed to improve recombinant protein expression. Oxford Genetics Ltd has a track record of delivering DNA design and cell line development projects for the improved production of antibodies, vaccines and viruses.

ASGCT

ASGCT is the primary membership organization for scientists, physicians, patient advocates, and professionals involved in gene and cell therapy. The Society’s mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease. ASGCT also publishes the Molecular Therapy family of journals, including Molecular Therapy – Oncolytics, an online open-access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.

GOLD Partner

Replimune

Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumor tissue, while at the same time inducing a potent, patient-specific, anti-tumor immune response. Oncolytic viruses have the unique ability to generate a systemic immune response to the patient’s particular complement of tumor antigens, including neoantigens, with a truly off-the-shelf and practical approach. This potentially solves a current ‘holy grail’ of immune-oncology research, i.e. the development of truly practical patient-specific tumor neoantigen vaccines. Oncolytic viruses also potently activate innate immunity, including through TLRs and STING, meaning that altogether oncolytic immunotherapies bundle multiple immune oncology approaches into one. This particularly the case if, as for Replimune’s products, these are then used to also deliver multiple therapeutic proteins to tumors too.

Vyriad

Vyriad is a clinical stage, biopharmaceutical company based in Rochester, MN.  Founded by a passionate team of researchers and clinicians with extensive experience in development and translation of novel oncolytic therapies for the treatment of cancer.

Vyriad strives to develop potent, safe and cost-effective cancer therapies in areas of unmet need. We are developing powerful Oncolytic virus therapies, utilizing engineered viruses designed to selectively and rapidly destroy cancer.  We have exclusively licensed the powerful Vesicular Stomatitis Virus (VSV) and measles Virus (MV) Oncolytic platforms.

Turnstone

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. The company’s first-of-its-kind investigational oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, with the goal of preventing recurrence and delivering a cure. Turnstone Biologics’ robust pipeline of early-stage investigational therapies, based on its Maraba (MG1) oncolytic virus platform, are in development for solid tumors. In addition to the MAGEA3 therapy currently in the clinic, Turnstone Biologics expects to enter the clinic in early 2018 with a therapy for HPV+ cancers, and is also developing medicines for multiple other cancers. These immunotherapies are being evaluated as monotherapies and in combination with other cancer therapies, including checkpoint inhibitors. Turnstone has been financed by Versant Ventures, OrbiMed, F-Prime Capital Partners and FACIT. Turnstone recently entered a research, option and license agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company, whereby AbbVie obtained an exclusive option to license up to three of Turnstone’s next-generation oncolytic viral immunotherapies